Photoacoustic imaging enables label-free real-time tumor microenvironment visualization in oncologyNew imaging technology helps doctors see tumor details in real time
Frontiers in MedicinePublished August 21, 2026Study authors: Yuwei Dong, Cuirong Li, Xiaoqin QianDOI ↗Editorial oversight: Dr. Amelia Tan, PhD · Internal Medicine & Chronic Disease
AI-generated summary of the cited source, checked by automated accuracy review.
How we work
Share
Key Takeaway
Consider PAI as an emerging imaging tool for tumor characterization, but recognize its current technical limitations and lack of clinical validation.
This systematic review synthesizes the current state of photoacoustic imaging (PAI) in oncology, focusing on its capabilities for label-free, real-time visualization of tumor microenvironments. The review covers PAI's ability to depict hemoglobin distribution, oxygen saturation, and nuclear morphology, which are critical for preoperative tumor characterization, intraoperative margin assessment, and detection of vascular involvement. These features position PAI as a promising tool for tumor diagnosis and surgical guidance.
The authors highlight that PAI offers a unique advantage by providing real-time, label-free imaging without the need for exogenous contrast agents, potentially improving surgical precision. However, the review is largely descriptive, summarizing potential capabilities rather than presenting clinical trial results. The primary outcomes and effect sizes are not reported, indicating that this is an early-stage assessment of the technology's promise.
Key limitations identified include limited penetration depth, laser safety concerns, reconstruction artifacts, and a lack of standardization across systems. These technical hurdles currently restrict widespread clinical adoption. The authors do not report on adverse events or patient-level outcomes, underscoring the need for further clinical validation.
For clinicians, PAI remains an investigational modality. While its ability to visualize tumor physiology in real time is compelling, the evidence is insufficient to support immediate clinical use. The review serves as a foundational overview, but future studies must address standardization and safety before PAI can be integrated into routine oncology practice.
How this fits prior evidence
This systematic review on photoacoustic imaging (PAI) in oncology extends prior coverage by introducing a novel imaging modality that complements existing molecular and physical approaches. Unlike the CXCL16/CXCR6 axis, which highlights a molecular pathway with bidirectional regulatory effects, PAI offers a label-free, real-time visualization of tumor microenvironments, addressing a gap in non-invasive imaging techniques. Similarly, while Tumor Treating Fields and pulsed electric fields modulate cell death and immune microenvironment through specific pathways, PAI provides structural and functional information (hemoglobin distribution, oxygen saturation) that could guide surgical decisions. The review's focus on technical limitations, such as penetration depth and lack of standardization, contrasts with the more mature evidence for electric fields, indicating PAI is at an earlier stage of development.
When a surgeon operates on a tumor, they need to know exactly where the cancer ends and healthy tissue begins. They also need to know if the area has enough blood flow or oxygen to heal properly. This is where photoacoustic imaging comes in. It uses light pulses to create images of these specific details inside the body.
This technology allows doctors to see things like hemoglobin distribution and oxygen levels without needing special labels or dyes. By looking at these markers, surgeons can get a better sense of the tumor's environment during surgery. This could help them make quicker decisions about where to cut and how to manage the area.
While this tool shows promise for guiding surgery and diagnosing tumors, it is not perfect yet. The technology still faces hurdles like limited depth of penetration into the body and a lack of standard rules for how it is used. It is currently being explored as a way to improve surgical guidance rather than replacing existing methods.
What this means for you:
Photoacoustic imaging helps surgeons see oxygen levels and blood flow in tumors during surgery.
Common questions
What can this new imaging see inside a tumor?
This technology allows doctors to see the tumor's microenvironment in real time. Specifically, it shows how oxygen is distributed, where blood is flowing (hemoglobin distribution), and the shape of cell nuclei. These details help surgeons understand the makeup of the tumor during an operation.
How does this imaging help during surgery?
The technology can provide guidance for surgeons by helping them characterize tumors before they start and check the edges of a tumor during the procedure. It also helps them see if blood vessels are involved in the area, which is important for planning the surgery.
What are the current limits of this technology?
There are still some hurdles to overcome before it can be used everywhere. These include how deep the light can go into the body, ensuring laser safety, and creating clear images without artifacts. There is also a need for more standard ways to use the equipment.
Photoacoustic imaging (PAI) is an emerging hybrid modality that combines high-contrast optical imaging with high-resolution ultrasound imaging, offering significant potential for tumor diagnosis and surgical guidance. This review provides a concise and focused overview of the principles, technological advancements, and clinical applications of PAI in oncology. We begin by introducing the basic mechanism of PAI, including the photoacoustic effect and the differentiation between the NIR-I and NIR-II imaging windows. The review then systematically examines the role of PAI in preoperative tumor characterization, intraoperative margin assessment, and vascular involvement detection. Emphasis is placed on how PAI enables label-free, real-time visualization of tumor microenvironments, including hemoglobin distribution, oxygen saturation, and nuclear morphology. Key technological innovations, such as multispectral optoacoustic tomography (MSOT) and optical-resolution photoacoustic microscopy (OR-PAM), are discussed with a focus on their inherent depth-resolution trade-offs. We also highlight recent advances in exogenous contrast agents and their potential for molecular imaging. critically evaluating their stability, toxicity, and translational hurdles. By synthesizing current evidence and directly addressing key technical and clinical limitations—including penetration depth, laser safety, reconstruction artifacts, and lack of standardization—this review provides a comprehensive and critical evaluation of PAI’s capabilities, limitations, and future directions in tumor diagnosis and surgical treatment.
